Delphi panel for consensus on the optimal management of dabrafenib plus trametinib-related pyrexia in patients with melanoma
Name:
36339928.pdf
Size:
301.8Kb
Format:
PDF
Description:
Identified with Open Access button
Affiliation
Consultant Medical Oncologist, Velindre University NHS Trust, Velindre Cancer Centre, Velindre Road, Cardiff, Wales CF14 2TL, UKIssue Date
2022
Metadata
Show full item recordAbstract
Purpose: Dabrafenib and trametinib combination therapy (dab + tram) is indicated to treat BRAF V600 mutation-positive unresectable/metastatic melanoma and as adjuvant treatment for resected stage III disease. Dab + tram-related pyrexia may require early therapy discontinuation. A modified Delphi panel was conducted to develop consensus on the optimal management of dab + tram-related pyrexia in patients with melanoma. Methods: In all, 10 UK oncologists experienced in melanoma management participated in a three-round modified Delphi study (Round 1: one-to-one interview; Rounds 2 and 3: email survey). In each round, participants rated the extent of their agreement with statements about defining and managing dab + tram-related pyrexia. Consensus was defined as >80% agreement for critical management (CM) and >60% for non-critical management (NCM) statements. Results: All 10 participants completed Round 1; 9 completed Rounds 2 and 3. Consensus was reached on 42/66 statements (20 CM and 22 NCM). Drug-related pyrexia was agreed as being strictly an elevation of body temperature, although other symptoms may be present (89% agreement). Panelists agreed on the need for simple and generic guidance on dab + tram-related pyrexia management that does not differentiate between patient groups (100%), and that management of first and second dab + tram-related pyrexia episodes should be the same regardless of treatment intent (100%). Regarding CM, participants agreed that both dab and tram should be interrupted for pyrexia (100%) without considering the use of steroids (89%); patients on dab + tram presenting to non-oncology services with pyrexia should be directed to an oncology-specific service as soon as possible and assessed for infection (100%). NCM statements on steroid use following dab + tram interruption and when to restart dab + tram did not reach consensus. Conclusions: These consensus statements provide a framework on optimal management of dab + tram-related pyrexia in patients with melanoma which should inform future guidelinesCitation
Frazer R, Gupta A, Herbert C, Payne M, Diaz-Mendoza S, Vincent SA, et al. Delphi panel for consensus on the optimal management of dabrafenib plus trametinib-related pyrexia in patients with melanoma. Therapeutic advances in medical oncology. 2022;14:17588359221127681. PubMed PMID: 36339928. Pubmed Central PMCID: PMC9629565. Epub 2022/11/08. eng.Journal
Therapeutic Advances in Medical OncologyDOI
10.1177/17588359221127681PubMed ID
36339928Additional Links
https://dx.doi.org/10.1177/17588359221127681Type
ArticleLanguage
enae974a485f413a2113503eed53cd6c53
10.1177/17588359221127681
Scopus Count
Collections
Related articles
- Retrospective Chart Review of Dabrafenib Plus Trametinib in Patients with Metastatic BRAF V600-Mutant Melanoma Treated in the Individual Patient Program (DESCRIBE Italy).
- Authors: Aglietta M, Chiarion-Sileni V, Fava P, Guidoboni M, Depenni R, Minisini A, Consoli F, Ascierto P, Rinaldi G, Banzi M, Marconcini R, Gueli R, Ferraresi V, Tucci M, Tonini G, Lo Re G, Guida M, Del Vecchio M, Marcon IG, Queirolo P
- Issue date: 2021 Nov
- Management of Pyrexia Associated with the Combination of Dabrafenib and Trametinib: Canadian Consensus Statements.
- Authors: Thawer A, Miller WH Jr, Gregorio N, Claveau J, Rajagopal S, Savage KJ, Song X, Petrella TM, On Behalf Of The Canadian Working Group
- Issue date: 2021 Sep 14
- Pyrexia in patients treated with dabrafenib plus trametinib across clinical trials in BRAF-mutant cancers.
- Authors: Schadendorf D, Robert C, Dummer R, Flaherty KT, Tawbi HA, Menzies AM, Banerjee H, Lau M, Long GV
- Issue date: 2021 Aug
- Improved pyrexia-related outcomes associated with an adapted pyrexia adverse event management algorithm in patients treated with adjuvant dabrafenib plus trametinib: Primary results of COMBI-APlus.
- Authors: Atkinson V, Robert C, Grob JJ, Gogas H, Dutriaux C, Demidov L, Gupta A, Menzies AM, Ryll B, Miranda F, Banerjee H, Lau M, Del Vecchio M
- Issue date: 2022 Mar
- Adverse Event Management in Patients with BRAF V600E-Mutant Non-Small Cell Lung Cancer Treated with Dabrafenib plus Trametinib.
- Authors: Chalmers A, Cannon L, Akerley W
- Issue date: 2019 Jul